GPs are the main providers of treatment for sexually transmitted infections (STIs) and blood-borne viruses (BBVs) in Australia. With chlamydia rates tripling in the last ten years, and an estimated 1 in 3 Australians living with chronic hepatitis B going undiagnosed, every GP should be actively testing for STIs and BBVs.

Regarded as one of the most important advances in hepatitis C in the last decade, three independent studies (one conducted by a team from Sydney), have shown that variation in the IL28B gene is the most crucial determinant of treatment outcome in chronic hepatitis C patients with genotype 1.